Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126
16 Jan 2024 //
GLOBENEWSWIRE
Adagene To Present Results of anti-CTLA-4 SAFEbody ADG126 with Pembrolizumab
04 Jan 2024 //
GLOBENEWSWIRE